Jansitin Duo

Metformin Hydrochloride/Sitagliptin, the active ingredients in Jansitin Duo, are a biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adult patients who need additional glycaemic control beyond diet and exercise.

GNH USA supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jansitin Duo combines metformin and sitagliptin to manage hyperglycaemia in type 2 diabetes.

- Type 2 diabetes mellitus: improves overall glycaemic control when diet and exercise are insufficient. - Adjunct to insulin therapy: helps lower required insulin doses while maintaining target glucose levels. - Combination with other oral antidiabetics: provides complementary mechanisms to further reduce blood glucose.

Jansitin Duo may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Mild hypoglycaemia: especially when used with sulfonylureas or insulin.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: can occur with concomitant insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Allergic reactions: rash, pruritus, or angio‑edema. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Renal impairment: worsening kidney function, particularly with metformin accumulation.

Before prescribing Jansitin Duo, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Renal function: assess baseline creatinine clearance and monitor periodically. - Hepatic disease: use with caution in patients with liver impairment. - Cardiovascular status: monitor for signs of heart failure, especially in elderly patients. - Concomitant hypoglycaemic agents: adjust doses of sulfonylureas or insulin to avoid low blood sugar. - Pregnancy and lactation: consider risk‑benefit ratio; consult current guidelines. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Jansitin Duo can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Phenformin or other contraindicated biguanides: increased risk of lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise sitagliptin plasma levels. - Iodinated contrast agents: can impair renal function, heightening metformin‑related risks.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycaemia; dose adjustment may be needed. - Insulin: may require reduction in insulin dose to prevent low glucose. - Diuretics (especially thiazides): can affect metformin clearance and electrolyte balance. - Cimetidine: may modestly increase sitagliptin exposure. - Alcohol: excessive intake can potentiate metformin‑associated lactic acidosis.